IMM Immupharma Plc

TIDMIMM

RNS Number : 0613R

Immupharma PLC

19 September 2017

FOR IMMEDIATE RELEASE 19 SEPTEMBER 2017

ImmuPharma PLC

("ImmuPharma" or the "Company")

NOTIFICATION OF INTERIM RESULTS

Date: 27 September 2017

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, confirms that it will be announcing its Interim results for the six months ended 30 June 2017 on Wednesday 27 September 2017.

-Ends-

 
 For further information please 
  contact: 
                                          + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)     7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                             + 44 (0) 7721 
    Twitter: @immupharma                   413496 
 
 
    Northland Capital Partners Limited 
    (Joint Broker) 
    Patrick Claridge, David Hignell, 
    Jamie Spotswood, Corporate Finance     +44 (0)20 3861 
    Rob Rees, Corporate Broking                      6625 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORXVLFFDKFLBBQ

(END) Dow Jones Newswires

September 19, 2017 02:01 ET (06:01 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024